INTERAZIONE DELLA CARBAMAZEPINA CON LA VALNOCTAMIDE: DATI 'IN VITRO' ED IN PAZIENTI CON EPILESSIA

Translated title of the contribution: Interaction of Carbamazepine with Valnoctamide: Data 'in vitro' and in patients with epilepsy

F. Pisani, A. Haj-Yehia, A. Fazio, C. Artesi, G. Oteri, E. Perucca, D. L. Kroetz, R. H. Levy, M. Bialer

Research output: Contribution to journalArticlepeer-review

Abstract

Valnoctamide (VCD), an over-the-counter tranquilizer which displays anticonvulsant activity in animal models was added at a daily dosage of 600 mg to six epileptic patients on carbamazepine (CBZ) therapy. During VCD treatment the serum levels of the active CBZ metabolite, i.e. CBZ-Epoxide, increased 5-fold on average (from 1,5 ± 0,7 μg/ml to 7,4 ± 4,4 μg/ml). In four patients this rise was associated with clinical signs of CBZ intoxication. In preparations of human liver microsomes VCD at therapeutic concentration inhibited the hydrolysis of styrene-oxide. Thus VCD is a potent inhibitor of the enzyme epoxide-hydrolase (IC50 = 15 μM).

Translated title of the contributionInteraction of Carbamazepine with Valnoctamide: Data 'in vitro' and in patients with epilepsy
Original languageItalian
Pages (from-to)159
Number of pages1
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number82-83
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Interaction of Carbamazepine with Valnoctamide: Data 'in vitro' and in patients with epilepsy'. Together they form a unique fingerprint.

Cite this